In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.
Shares in 2seventy bio were on the slide this morning after the US biotech said Seattle Children’s Therapeutics had paused a clinical trial of its T-cell therapy for acute
Johnson & Johnson’s appetite for building a new generation of CAR-T therapies for cancer shows no sign of being sated – its Janssen Biotech unit has just paid $245 mil
A pair of new guidance documents from UK cost-effectiveness authority NICE could see hundreds of more blood cancer patients eligible for treatment with CAR-T therapies fro
Nerve damage is a recognised side effect of some CAR-T therapies for cancer, and one that could be spotted early using a pen device developed by UK company Manus Neurodyna
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho